DNA damage increases sensitivity to Vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule- associated protein 4

Cancer Research

Volumn 59, Issue 15, 1999, Pages 3663-3670

  Zhang, Christine C ^a,b   Yang, Jin Ming ^a,b   Bash Babula, Judy ^b   White, Eileen ^b,c   Murphy, Maureen ^d   Levine, Arnold J ^e   Hait, William N ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DOXORUBICIN; MICROTUBULE ASSOCIATED PROTEIN 4; PACLITAXEL; PROTEIN P53; TAXANE DERIVATIVE; VINBLASTINE; VINCA ALKALOID;

ANIMAL CELL; ARTICLE; DNA DAMAGE; DRUG PROTEIN BINDING; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOPOLYMERS; BLEOMYCIN; BRIDGED COMPOUNDS; CYTARABINE; DNA DAMAGE; DNA, NEOPLASM; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; MICROTUBULES; NEOPLASM PROTEINS; PACLITAXEL; RATS; TAXOIDS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS; VINBLASTINE; VINCA ALKALOIDS;

EID: 0033178994     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. DeVita, V. T., Hellman, S., and Rosenberg, S. A. Cancer Principles and Practice of Oncology, Ed. 5, pp. 333-347. Philadelphia: Lippincott-Raven, 1997.
2. Barinaga, M. From bench top to bedside. Science (Washington DC), 278: 1036-1039, 1997.
3. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
4. Murphy, M., Hinman, A., and Levine, A. J. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev., 10: 2971-2980, 1996.
5. Zhang, C. C., Yang, J. M., White, E., Murphy, M., Levine, A., and Hait, W. N. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to Vinca alkaloids in p53 mutant cells. Oncogene, 16: 1617-1624, 1998.
6. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
7. Smith, K. T., and Camp, M. S. "Hit and run" transformation of mouse C127 cells by bovine papillomavirus type 4: the viral DNA is required for the initiation but not for maintenance of the transformed phenotype. Virology, 164: 39-47, 1988.
8. Debbas, M., and White, E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev., 7: 546-554, 1993.
9. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A., and Murphy, G. P. LnCAP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.
10. Webber, M. M., Bello, D., and Quader, S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications. Prostate, 30: 136-142, 1997.
11. Carroll, A. G., Voeller, H. J., Sugars, L., and Gelmann, E. P. p53 oncogene mutations in three human prostate cancer cell lines. Prostate, 23: 123-134, 1993.
12. McGowan-Jordan, I. J., Speevak, M. D., Blakey, D., and Chevrette, M. Suppression of tumorigenicity in human teratocarcinoma cell line PA-1 by introduction of chromosome 4. Cancer Res., 54: 2568-2572, 1994.
13. Kutteh, W. H., Miller, D. S., and Mathis, J. M. Immunologic characterization of tumor markers in human ovarian cancer cell lines. J. Soc. Gynecol. Invest., 3: 216-222, 1996.
14. Mihara, K., Miyazaki, M., Kondo, T., Fushimi, K., Tsuji, T., Inoue, Y., Fukaya, K., Ishioka, C., and Namba, M. Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory. Acta Med. Okayama, 51: 261-265, 1997.
15. Yaginuma, Y., and Westphal, H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res., 52: 4196-4199, 1992.
16. Scudiero, D. A., Shoemaker, R. H., Paul, K. D., Monks, A., Tierney, S., Nofziger, T. H., Currens, M. J., Seniff, D., and Boyd, M. R. Evaluation of a soluble tetrazolium/ formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res., 48: 4827-4833, 1988.
17. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods, 65: 55-63, 1983.
18. Hess, R., Plaumann, B., Lutum, A. S., Haessler, C., Heinz, B., Fritsche, M., and Brandner, G. Nuclear accumulation of p53 in response to treatment with DNA-damaging agents. Toxicol. Lett., 72: 43-52, 1994.
19. Fritsche, M., Haessler, C., and Brandner, G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene, 8: 307-318, 1993.
20. Gannon, J. V., Greaves, R., Iggo, R., and Lane, D. P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J., 9: 1595-1602, 1990.
21. Finney, D. J. Statistical Method in Biological Assay. London: Charles Griffin and Co., 1978.
22. Ford, J. M., Yang, J. M., and Hait, W. N. P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Cancer Treat. Res., 87: 3-38, 1996.
23. Gonzalez-Garay, M. L., and Cabral, F. Overexpression of an epitope-tagged β-tubulin in Chinese hamster ovary cells causes an increase in endogenous α-tubulin synthesis. Cell Motil. Cytoskeleton, 31: 259-272, 1995.
24. Parekh, H., Wiesen, K., and Simpkins, H. Acquisition of Taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem. Pharmacol., 53: 461-470, 1997.
25. Ohta, S., Nishio, K., Kubota, N., Ohmori, T., Funayama, Y., Ohira, T., Nakajima, H., Adachi, M., and Saijo, N. Characterization of a Taxol-resistant human small-cell lung cancer cell line. Jpn. J. Cancer Res., 85: 290-297, 1994.
26. Rowinsky, E. K., Donehower, R. C., Jones, R. J., and Tucker, R. W. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res., 48: 4093-4100, 1988.
27. Harrington, E. A., Fanidi, A., and Evan, G. I. Oncogenes and cell death. Curr. Opin. Genet. Dev., 4: 120-129, 1994.
28. Wu, G. S., and El-Diery, W. S. p53 and chemosensitivity. Nature (Lond.), 381: 713-716, 1996.
29. 2/M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.
30. Hawkins, D. S., Demers, G. W., and Galloway, D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56: 892-898, 1996.
31. Delia, D., Mizutani, S., Lamorte, G., Goi, K., Iwata, S., and Pierotti, M. A. p53 activity and chemotherapy. Nat. Med., 2: 724-725, 1996.
32. Bulinski, J. C., McGraw, T. E., Gruber, D., Nguyen, H. L., and Sheetz, M. P. Overexpression of MAP4 inhibits organelle motility and trafficking in vivo. J. Cell Sci., 110: 3055-3064, 1997.
33. Nguyen, H. L., Chari, S., Gruber, D., Lue, C. M., Chapin, S., and Bulinski, J. Overexpression of full- or partial-length MAP4 stabilizes microtubules and alters cell growth. J. Cell Sci., 110: 281-294, 1997.
34. Yoshida, T., Imanaka-Yoshida, K., Murofushi, H., Tanaka, J., Ito, H., and Inagaki, M. Microinjection of intact MAP-4 and fragments induces changes of the cytoskeleton in PtK2 cells. Cell Motil. Cytoskeleton, 33: 252-262, 1996.
35. Gewirtz, D. A. DNA damage, gene expression, growth arrest and cell death. Oncol. Res., 5: 397-408, 1993.
36. Hall, P. A., McKee, P. H., Menage, H. D., Dover, R., and Lane, D. P. High levels of p53 protein in UV-irradiated normal human skin. Oncogene, 8: 203-207, 1993.
37. Lee, J. M., and Bernstein, A. p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA, 90: 5742-5746, 1993.
38. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
39. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
40. Khil, M. S., Kim, J. H., Bricker, L. J., and Cerny, J. C. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy. Cancer J. Sci. Am., 3: 289-296, 1997.
41. Ryu, S., Gabel, M., Khil, M. S., Lee, Y. J., Kim, S. H., and Kim, J. H. Estramustine: a novel radiation enhancer in human carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys., 30: 99-104, 1994.
42. Choy, H., and Browne, M. J. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin. Oncol., 22: 70-74, 1995.
43. Elomaa, L., Joensuu, H., Kulmala, J., Klemi, P., and Grenman, R. Squamous cell carcinoma is highly sensitive to taxol, a possible new radiation sensitizer. Acta Otolaryngol., 115: 340-344, 1995.
44. Lokeshwar, B. L., Ferrell, S. M., and Block, N. L. Enhancement of radiation response of prostatic carcinoma by Taxol: therapeutic potential for late-stage malignancy. Anticancer Res., 15: 93-98, 1995.
45. Steren, A., Sevin, B. U., Perras, J., Angioli, R., Nguyen, H., Guerra, L., Koechli, O., and Averette, H. E. Taxol sensitizes human ovarian cancer cells to radiation. Gynecol. Oncol., 48: 252-258, 1993.
46. Liebmann, J., Cook, J. A., Fisher, J., Teague, D., and Mitchell, J. B. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J. Natl. Cancer Inst., 86: 441-446, 1994.
47. Stromberg, J. S., Lee, Y. J., Armour, E. P., Martinez, A. A., and Corry, P. M. Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines. Cancer (Phila.), 75: 2262-2268, 1995.
48. Erlich, E., McCall, A. R., Potkul, R. K., Walter, S., and Vaughan, A. Paclitaxel is only a weak radiosensitizer of human cervical carcinoma cell lines. Gynecol. Oncol, 60: 251-254, 1996.
49. Chapin, S. J., Lue, C. M., Yu, M. T., and Bulinski, J. C. Differential expression of alternatively spliced forms of MAP4: a repertoire of structurally different microtubule-binding domains. Biochemistry, 34: 2289-2301, 1995.
50. Lobert, S., Vulevic, B., and Correia, J. J. Interaction of Vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry, 35: 6806-6814, 1996.